{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:48:04Z","timestamp":1790837284455,"version":"4.1.0"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"QED Therapeutics"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Achondroplasia is the most common short-limbed skeletal dysplasia resulting from gain-of-function pathogenic variants in fibroblast growth factor receptor 3 ( FGFR3) gene, a negative regulator of endochondral bone formation. Most treatment options are symptomatic, targeting medical complications. Infigratinib is an orally bioavailable, FGFR1\u20133 selective tyrosine kinase inhibitor being investigated as a direct therapeutic strategy to counteract FGFR3 overactivity in achondroplasia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The main objective of PROPEL is to collect baseline data of children with achondroplasia being considered for future enrollment in interventional studies sponsored by QED Therapeutics. The objectives of PROPEL 2 are to obtain preliminary evidence of safety and efficacy of oral infigratinib in children with achondroplasia, to identify the infigratinib dose to be explored in future studies, and to characterize the pharmacokinetic (PK) profile of infigratinib and major metabolites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>PROPEL (NCT04035811) is a prospective, noninterventional clinical study designed to characterize the natural history and collect baseline data of children with achondroplasia over 6\u221224 months. PROPEL 2 (NCT04265651), a prospective, phase II, open-label study of infigratinib in children with achondroplasia, consists of a dose-escalation, dose-finding, and dose-expansion phase to confirm the selected dose, and a PK substudy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis:<\/jats:title>\n                    <jats:p>Children aged 3\u221211 years with achondroplasia who completed \u2a7e6 months in PROPEL are eligible for PROPEL 2. Primary endpoints include treatment-emergent adverse events and change from baseline in annualized height velocity. Four cohorts at ascending dose levels are planned for dose escalation. The selected dose will be confirmed in the dose-expansion phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics:<\/jats:title>\n                    <jats:p>PROPEL and PROPEL 2 are being conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, principles of the Declaration of Helsinki, and relevant human clinical research and data privacy regulations. Protocols have been approved by local health authorities, ethics committees, and institutions as applicable. Parents\/legally authorized representatives are required to provide signed informed consent; signed informed assent by the child is also required, where applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>PROPEL and PROPEL 2 will provide preliminary evidence of the safety and efficacy of infigratinib as precision treatment of children with achondroplasia and will inform the design of future studies of FGFR-targeted agents in achondroplasia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT04035811; NCT04265651.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1759720x221084848","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T08:00:23Z","timestamp":1647849623000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":47,"title":["Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5105-8427","authenticated-orcid":false,"given":"Ravi","family":"Savarirayan","sequence":"first","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Parkville, VIC 3052, Australia"},{"name":"University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"De Bergua","sequence":"additional","affiliation":[{"name":"Unidad de Cirug\u00eda Artrosc\u00f3pica (UCA), Hospital Vithas Vitoria, Vitoria-Gasteiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Arundel","sequence":"additional","affiliation":[{"name":"Sheffield Children\u2019s NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McDevitt","sequence":"additional","affiliation":[{"name":"NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Cormier-Daire","sequence":"additional","affiliation":[{"name":"Imagine Institute, H\u00f4pital Necker-Enfants Malades, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrinda","family":"Saraff","sequence":"additional","affiliation":[{"name":"Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mars","family":"Skae","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Delgado","sequence":"additional","affiliation":[{"name":"Campus de Teatinos sin n\u00famero, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Leiva-Gea","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Malaga, Spain"},{"name":"Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Santos-Simarro","sequence":"additional","affiliation":[{"name":"Instituto de Gen\u00e9tica M\u00e9dica y Molecular (INGEMM), Unidad Multidisciplinar de Displasias Esquel\u00e9ticas (UMDE), Hospital Universitario La Paz, Instituto de Investigaci\u00f3n del Hospital Universitario La Paz (IdiPAZ), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de enfermedades raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Salles","sequence":"additional","affiliation":[{"name":"H\u00f4pital des Enfants, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Nicolino","sequence":"additional","affiliation":[{"name":"H\u00f4pital Femme M\u00e8re Enfant, Hospices Civils de Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Rossi","sequence":"additional","affiliation":[{"name":"Lyon University Hospital, Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kannu","sequence":"additional","affiliation":[{"name":"Stollery Children\u2019s Hospital, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Bober","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Hospital, Wilmington, DE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John","family":"Phillips","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Saal","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[{"name":"UCSF Benioff Children\u2019s Hospital Oakland, Oakland, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Burren","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Gotway","sequence":"additional","affiliation":[{"name":"Children\u2019s Medical Center Dallas, Texas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Cho","sequence":"additional","affiliation":[{"name":"QED Therapeutics Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Muslimova","sequence":"additional","affiliation":[{"name":"QED Therapeutics Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Weng","sequence":"additional","affiliation":[{"name":"QED Therapeutics Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rogoff","sequence":"additional","affiliation":[{"name":"QED Therapeutics Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hoover-Fong","sequence":"additional","affiliation":[{"name":"School of Medicine, Johns Hopkins University, Baltimore, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melita","family":"Irving","sequence":"additional","affiliation":[{"name":"Guy\u2019s and Saint Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"bibr1-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61090-3"},{"key":"bibr2-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.32485"},{"key":"bibr3-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115872"},{"key":"bibr4-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0972-6"},{"key":"bibr5-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-017-0347-2"},{"key":"bibr6-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1177\/088307389000500203"},{"key":"bibr7-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.35.9.705"},{"key":"bibr8-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/88.2.364"},{"key":"bibr9-1759720X221084848","first-page":"368","volume":"56","author":"Bellus GA","year":"1995","journal-title":"Am J Hum Genet"},{"key":"bibr10-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90302-6"},{"key":"bibr11-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2009.04.003"},{"key":"bibr12-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00595-x"},{"key":"bibr13-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.265"},{"key":"bibr14-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0229"},{"key":"bibr15-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83926"},{"key":"bibr16-1759720X221084848","volume-title":"American Society of Human Genetics 69th annual meeting","author":"Legeai-Mallet L"},{"key":"bibr17-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1111\/rssc.12089"},{"key":"bibr18-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-020-00741-6"},{"key":"bibr19-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5009"},{"key":"bibr20-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.552"},{"key":"bibr21-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.20127"},{"key":"bibr22-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2019.103816"},{"key":"bibr23-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813446"},{"key":"bibr24-1759720X221084848","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31541-5"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X221084848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X221084848","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X221084848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:38:19Z","timestamp":1777588699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X221084848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":24,"alternative-id":["10.1177\/1759720X221084848"],"URL":"https:\/\/doi.org\/10.1177\/1759720x221084848","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"1759720X221084848"}}